Perspective Therapeutics (CATX) financial statements
Net income was -$103M.
Free cash flow was -$95M.
The diluted share count rose 1242% over the period (dilution).
Revenue and free cash flow
Fiscal years, $ billions.
Income statement
Fiscal years, from Perspective Therapeutics's 10-K filings with the SEC.
| Fiscal year | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $5M | $6M | $7M | $10M | $10M | $11M | $0 | $1M | — | — |
| Cost of revenue | $4M | $4M | $4M | $5M | $5M | $6M | — | — | — | — |
| Gross profit | $838,000 | $2M | $3M | $5M | $5M | $0 | $0 | $1M | — | — |
| Research and development | $965,000 | $2M | $1M | $1M | $1M | $850,000 | $881,000 | $21M | $42M | $84M |
| Selling, general and admin | $6M | $7M | $7M | $8M | $7M | $8M | $7M | $21M | $27M | $30M |
| Operating income | -$6M | -$7M | -$5M | -$3M | -$3M | -$6M | -$9M | -$41M | -$91M | -$114M |
| Interest expense | $0 | — | — | — | — | $0 | $0 | $84,000 | — | — |
| Pre-tax income | — | — | — | — | — | -$6M | -$8M | -$40M | -$80M | -$104M |
| Income tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | -$3M | -$2M | -$793,000 |
| Net income | -$6M | -$7M | -$5M | -$3M | -$3M | -$7M | -$11M | -$47M | -$79M | -$103M |
| EPS (diluted) | -$1.10 | -$1.20 | -$0.80 | -$0.50 | -$0.30 | -$0.50 | -$0.80 | -$1.74 | -$1.23 | -$1.40 |
| Diluted shares | 6M | 6M | 7M | 7M | 10M | 14M | 14M | 27M | 64M | 74M |
| Gross margin | 17.6% | 31.1% | 41.7% | 52.9% | 50.9% | 0.0% | — | 100.0% | — | — |
| Operating margin | -132.5% | -113.6% | -71.8% | -35.9% | -34.3% | -59.5% | — | -2855.0% | — | — |
| Net margin | -129.4% | -113.1% | -70.3% | -35.6% | -33.7% | -67.4% | — | -3243.2% | — | — |
Balance sheet
Fiscal years, from Perspective Therapeutics's 10-K filings with the SEC.
| Fiscal year | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and short-term investments | $9M | $3M | $5M | $2M | $64M | $56M | $44M | $9M | $227M | $145M |
| Receivables | $726,000 | $1M | $1M | $2M | $2M | $2M | $1M | $1M | $116,000 | $6,000 |
| Inventory | $323,000 | $494,000 | $530,000 | $645,000 | $980,000 | $1M | $1M | — | — | — |
| Total current assets | $10M | $5M | $7M | $6M | $67M | $59M | $53M | $17M | $231M | $148M |
| Property, plant and equipment | $1M | $1M | $2M | $2M | $2M | $2M | $371,000 | $6M | $57M | $77M |
| Goodwill | — | — | — | — | — | — | $0 | $24M | $0 | — |
| Total assets | $12M | $7M | $9M | $9M | $70M | $64M | $58M | $98M | $341M | $267M |
| Total current liabilities | $1M | $2M | $1M | $2M | $2M | $2M | $3M | $16M | $18M | $29M |
| Total liabilities | $2M | $2M | $2M | $3M | $3M | $3M | $3M | $23M | $50M | $60M |
| Shareholders' equity | $11M | $5M | $8M | $6M | $67M | $61M | $55M | $75M | $291M | $207M |
| Net debt | -$6M | -$3M | -$5M | -$2M | -$64M | -$56M | -$21M | -$9M | -$62M | -$31M |
Cash flow
Fiscal years, from Perspective Therapeutics's 10-K filings with the SEC.
| Fiscal year | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$6M | -$6M | -$5M | -$4M | -$3M | -$8M | -$10M | -$37M | -$18M | -$82M |
| Capital spending | $549,000 | $337,000 | $444,000 | $273,000 | $381,000 | $266,000 | $282,000 | $1M | $54M | $13M |
| Free cash flow | -$6M | -$6M | -$5M | -$4M | -$3M | -$8M | -$11M | -$38M | -$73M | -$95M |
| Stock-based compensation | $372,000 | $404,000 | $420,000 | $495,000 | $386,000 | $1M | $983,000 | $4M | $5M | $9M |
| Free cash flow margin | -131.5% | -102.1% | -75.1% | -40.4% | -32.0% | -73.9% | — | -2648.9% | — | — |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for CATX.
Open CATX in InvestinglyQuestions
How much free cash flow does Perspective Therapeutics generate?
-$95M in fiscal 2025 (operating cash flow minus capital spending).
From Perspective Therapeutics's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.